{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-027122","form_type":"8-K","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.224983+00:00","generated_at":"2026-06-12T01:46:10.734271+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Processa Pharmaceuticals appoints George Ng as CEO; COO Floyd to resign Aug 31","bullets":["George Ng appointed CEO and director effective Aug 8, 2023; previously president/COO of Calidi Biotherapeutics.","David Young steps down as CEO but remains President of R&D and board member; focuses on NGC drugs.","R. Michael Floyd resigns as COO by mutual agreement, effective August 31, 2023.","Ng receives $400k base salary, up to $100k bonus, and 800k RSUs (400k time-vest, 400k performance-based).","Ng previously led Scilex through $140M financing, FDA approval, and sale; holds JD from Notre Dame."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-027122","json":"https://secwatch.observer/filing/0001493152-23-027122.json","markdown":"https://secwatch.observer/filing/0001493152-23-027122.md","text":"https://secwatch.observer/filing/0001493152-23-027122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000149315223027122/0001493152-23-027122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000149315223027122/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:46:10.734271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7d446bbe95","claim":"George Ng was appointed as director at Processa Pharmaceuticals, Inc..","evidence_excerpt":"announced the appointment of Mr. George Ng as its Chief Executive Officer and a director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533743/000149315223027122/0001493152-23-027122-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"9425a1b3dc","claim":"David Young changed role as President of Research and Development at Processa Pharmaceuticals, Inc..","evidence_excerpt":"Dr. David Young will continue with the Company as a member of the Board of Directors and as the Company’s President of Research and Development.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533743/000149315223027122/0001493152-23-027122-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Role","value":"President of Research and Development"}],"fact_type":"executive_change"},{"claim_id":"c27724d94c","claim":"George Ng was appointed as Chief Executive Officer at Processa Pharmaceuticals, Inc..","evidence_excerpt":"announced the appointment of Mr. George Ng as its Chief Executive Officer and a director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533743/000149315223027122/0001493152-23-027122-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c6f7520e21","claim":"R. Michael Floyd resigned as Chief Operating Officer at Processa Pharmaceuticals, Inc..","evidence_excerpt":"Mr. R. Michael Floyd resigned as Chief Operating Officer of the Company, effective August 31, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533743/000149315223027122/0001493152-23-027122-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}